Tandem Diabetes Care - TNDM Stock Forecast, Price & News

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Tandem Diabetes Care Stock Up 3.0 %

Tandem Diabetes Care stock opened at $55.46 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 5.36 and a current ratio of 6.00. Tandem Diabetes Care has a 52-week low of $52.08 and a 52-week high of $155.86. The firm has a 50 day moving average price of $60.28 and a two-hundred day moving average price of $88.40. The firm has a market cap of $3.55 billion, a price-to-earnings ratio of -252.09 and a beta of 0.80.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on TNDM shares. Lake Street Capital reduced their price target on shares of Tandem Diabetes Care from $200.00 to $150.00 in a research note on Thursday, August 4th. SVB Leerink restated a "market perform" rating on shares of Tandem Diabetes Care in a research note on Monday, April 18th. Cowen reduced their price target on shares of Tandem Diabetes Care from $141.00 to $107.00 in a research note on Thursday, August 4th. Oppenheimer cut their target price on shares of Tandem Diabetes Care from $142.00 to $130.00 in a research report on Thursday, May 5th. Finally, TheStreet downgraded shares of Tandem Diabetes Care from a "c-" rating to a "d+" rating in a research report on Monday, June 13th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $103.36.

Insiders Place Their Bets

In other Tandem Diabetes Care news, COO David B. Berger sold 10,097 shares of the firm's stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $65.02, for a total transaction of $656,506.94. Following the completion of the transaction, the chief operating officer now owns 2,457 shares in the company, valued at approximately $159,754.14. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Tandem Diabetes Care news, COO David B. Berger sold 10,097 shares of the firm's stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $65.02, for a total transaction of $656,506.94. Following the completion of the transaction, the chief operating officer now owns 2,457 shares in the company, valued at approximately $159,754.14. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Kim D. Blickenstaff sold 10,762 shares of the firm's stock in a transaction that occurred on Tuesday, May 17th. The stock was sold at an average price of $92.91, for a total transaction of $999,897.42. Following the transaction, the director now owns 205,190 shares of the company's stock, valued at approximately $19,064,202.90. The disclosure for this sale can be found here. Company insiders own 2.20% of the company's stock.